Bäcker A E, Breimer M E, Samuelsson B E, Holgersson J
Department of Clinical Chemistry and Transfusion Medicine, University of Göteborg, Sahlgrenska Hospital, Sweden.
Glycobiology. 1997 Oct;7(7):943-53. doi: 10.1093/glycob/7.7.943.
Non-acid glycosphingolipids were isolated from small intestinal epithelial cells of a single blood group A pig. One very predominant blood group compound was obtained chemically pure upon HPLC fractionation. It was characterized by mass spectrometry and 1H NMR spectroscopy to be the type 1 chain blood group A hexaglycosylceramide. Support for the presence of minute amounts of additional A glycolipids was obtained by mass spectrometry and immunostaining of TLC plates with anti-A antibodies specific for A type 2 chain, A type 3 and 4 chain, and the ALe(b) determinant. Among precursor chains, globoside (type 4) and lactotetraosylceramide (type 1) were immunologically identified, whereas no neolactotetraosylceramide (type 2) and gangliotetraosylceramide reactivities were detected. We addressed the question whether the predominant expression of type 1 chain based A glycolipids reflects a restricted glycolipid precursor chain specificity of the alpha 1-2 fucosyl- and/or the alpha 1-3 N-acetylgalactosaminyltransferases, or if the biosynthesis of the precursor chains themselves is regulated. All precursor core saccharides, lacto- (type 1), neolacto-(type 2), and gangliotetraosylceramide as well as globopentaosylceramide (type 4), could serve as acceptors for fucose in vitro when a crude microsomal fraction obtained from mechanically released, porcine intestinal epithelial cells was used as an enzyme source. Under the same conditions an N-acetylgalactosamine residue could be transferred to the blood group H structures based on these core saccharide chains. Lactotriaosylceramide, but not gangliotriaosylceramide, could serve as an acceptor for UDP-galactose. When the product was digested with beta-galactosidase (EC 3.2.1.23) from S.pneumoniae, under conditions where it specifically cleaves Gal beta 1-4 residues, approximately 40% of the radioactivity was cleaved off, indicating that a substantial amount of neolactotetraosylceramide was made in vitro, as opposed to the predominance of lactotetraosylceramide-based structures found in vivo.
从一头血型为A的猪的小肠上皮细胞中分离出非酸性糖鞘脂。通过高效液相色谱(HPLC)分级分离得到一种非常主要的血型化合物,其化学纯度较高。通过质谱和1H核磁共振光谱对其进行表征,确定其为1型链血型A六糖基神经酰胺。通过质谱以及用针对2型链、3型和4型链以及A Leb(b)决定簇的抗A抗体对薄层层析板进行免疫染色,证实存在微量的其他A糖脂。在前体链中,通过免疫鉴定出了球苷脂(4型)和乳糖四糖基神经酰胺(1型),而未检测到新乳糖四糖基神经酰胺(2型)和神经节四糖基神经酰胺的反应性。我们探讨了基于1型链的A糖脂的主要表达是反映了α1-2岩藻糖基转移酶和/或α1-3 N-乙酰半乳糖胺基转移酶对糖脂前体链特异性的限制,还是前体链自身的生物合成受到调控这一问题。当使用从机械分离的猪小肠上皮细胞获得的粗微粒体部分作为酶源时,所有前体核心糖,乳糖-(1型)、新乳糖-(2型)、神经节四糖基神经酰胺以及球戊糖基神经酰胺(4型),在体外都可以作为岩藻糖的受体。在相同条件下,N-乙酰半乳糖胺残基可以转移到基于这些核心糖链的血型H结构上。乳糖三糖基神经酰胺,而不是神经节三糖基神经酰胺,可以作为UDP-半乳糖的受体。当产物用肺炎链球菌的β-半乳糖苷酶(EC 3.2.1.23)消化时,在其特异性切割Galβ1-4残基的条件下,约40%的放射性被切割掉,这表明在体外合成了大量的新乳糖四糖基神经酰胺,这与体内发现的以乳糖四糖基神经酰胺为基础的结构占主导地位形成对比。